Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis

T

Tanta University

Status

Unknown

Conditions

Spontaneous Bacterial Peritonitis

Treatments

Other: serum amyloid A level

Study type

Observational

Funder types

Other

Identifiers

NCT02759497
sbp diagnosis

Details and patient eligibility

About

One of the most common and serious complications in decompensated cirrhotic patients (DCPs) is bacterial infection.The most common infections in DCPs are cases of spontaneous bacterial peritonitis (SBP), which account for 40% 70% of cases, followed by urinary tract infections, pneumonia and cellulitis. Serum amyloid A (SAA) and C-reactive protein (CRP) are acute-phase proteins predominantly produced and secreted by hepatocytes. Other cells including lymphocytes, monocytes, and macrophages can also produce these proteins. The induction of SAA and CRP synthesis is triggered by a number of cytokines, chiefly IL-6, which is released from a variety of cell types, but mainly from macrophages and monocytes at inflammatory sites

Full description

Increased serum CRP and SAA levels have been found in a number of disorders, including bacterial infections, malignancies tissue injuries and tissue rejection. Therefore, new studies of early diagnosis, prevention and treatment are needed to improve clinical outcomes.

Enrollment

100 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

• Decompansated cirrhosis with ascites, defined by a combination of any of the following:

  • Laboratory findings
  • Endoscopic results
  • Ultrasound
  • Histology

Exclusion criteria

  • Creatinine>1.5 mg/dl
  • Other infection e.grespiratory,UTI ,gastrointestinal and skin infection.
  • Hepatocellular carcinoma
  • Other extrahepatic malignancy e.g ; chest
  • Any significant psychiatric illness or other medical comorbidity.
  • Any degenerative diseases.

Trial design

100 participants in 2 patient groups

Serum amyloid A level in SBP
Description:
serum amyloid A level
Treatment:
Other: serum amyloid A level
Serum amyloid A level in cirrhosis
Description:
Serum amyloid A level
Treatment:
Other: serum amyloid A level

Trial contacts and locations

1

Loading...

Central trial contact

Sherief Abd-Elsalam, Consultant

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems